false 0000313616 0000313616 2023-01-09 2023-01-09 0000313616 us-gaap:CommonStockMember 2023-01-09 2023-01-09 0000313616 us-gaap:SeriesBPreferredStockMember 2023-01-09 2023-01-09 0000313616 dhr:A17SeniorNotesDue2024Member 2023-01-09 2023-01-09 0000313616 dhr:A0.2SeniorNotesDue2026Member 2023-01-09 2023-01-09 0000313616 dhr:A21SeniorNotesDue2026Member 2023-01-09 2023-01-09 0000313616 dhr:A1.2SeniorNotesDue2027Member 2023-01-09 2023-01-09 0000313616 dhr:A0.45SeniorNotesDue2028Member 2023-01-09 2023-01-09 0000313616 dhr:A25SeniorNotesDue2030Member 2023-01-09 2023-01-09 0000313616 dhr:A0.75SeniorNotesDue2031Member 2023-01-09 2023-01-09 0000313616 dhr:A1.35SeniorNotesDue2039Member 2023-01-09 2023-01-09 0000313616 dhr:A1.8SeniorNotesDue2049Member 2023-01-09 2023-01-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 8-K
__________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 9, 2023
__________________

DANAHER CORPORATION
| (Exact Name of Registrant as Specified in Its Charter) |

__________________

Delaware |  | 001-08089 |  | 59-1995548
(State or Other Jurisdiction of Incorporation) |  | (Commission File Number) |  | (IRS Employer Identification No.)
2200 Pennsylvania Avenue, NW |  |  |  | 20037-1701
Suite 800W |  |  |
Washington, | DC |  |  |
(Address of Principal Executive Offices) |  |  |  | (Zip Code)

202-828-0850
(Registrant’s Telephone Number, Including Area Code)

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

__________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, $0.01 par value | DHR | New York Stock Exchange
5.00% Mandatory Convertible Preferred Stock, Series B, without par value | DHR.PRB | New York Stock Exchange
1.700% Senior Notes due 2024 | DHR 24 | New York Stock Exchange
0.200% Senior Notes due 2026 | DHR/26 | New York Stock Exchange
2.100% Senior Notes due 2026 | DHR 26 | New York Stock Exchange
1.200% Senior Notes due 2027 | DHR/27 | New York Stock Exchange
0.450% Senior Notes due 2028 | DHR/28 | New York Stock Exchange
2.500% Senior Notes due 2030 | DHR 30 | New York Stock Exchange
0.750% Senior Notes due 2031 | DHR/31 | New York Stock Exchange
1.350% Senior Notes due 2039 | DHR/39 | New York Stock Exchange
1.800% Senior Notes due 2049 | DHR/49 | New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company |  | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 | RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On January 9, 2023, in advance of a public webcast presentation at the J.P. Morgan Healthcare Conference on January 10, 2023 Danaher Corporation issued a press release regarding the Company’s anticipated financial performance for the fourth quarter of 2022 and furnished pursuant to Item 2.02 of Form 8-K such press release as well as the presentation slides attached hereto, each of which is incorporated by reference herein. The presentation slides attached hereto contain certain information regarding Danaher’s anticipated financial performance for 2022.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS
(c) | Exhibits:
Exhibit No. |  | Description
99.1 |  | Press release — “Danaher CEO to Comment on Financial Performance”
99.1PRE |  | Selected Danaher Presentation Slides for J.P. Morgan Healthcare Conference on January 10, 2023
104 |  | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  | DANAHER CORPORATION
Date: | January 9, 2023 | By: | /s/ Matthew R. McGrew
|  |  | Matthew R. McGrew
|  |  | Executive Vice President and Chief Financial Officer